Woodbridge Township

Researchers are evaluating outcomes in female patients with acute thoracolumbar compression fractures, focusing on how pain is managed and how well patients can function after injury. This observational study tracks patients whose fractures occurred within the last 3 months or less. The study aims to measure pain levels using the Numeric Rating Scale NRS and Brief Pain Inventory BPI, and quality of life through the PROMIS questionnaire at multiple time points before and after intervention. Participants will receive treatment using the commercially available SPRINT Peripheral Nerve Stimulation PNS system for 60 days. Pain and quality of life will be assessed prior to the intervention, then again at 2 weeks, 3 months, and 6 months after PNS implantation. The primary focus is on pain reduction, while secondary outcomes include improvements in function and quality of life as reported by participants through digital data collection. During the study, participants will complete assessments of pain and function at specified intervals. These include questionnaires like the PROMIS and patient-reported outcome measures collected via CareSense, a digital system. Researchers will monitor changes in pain scores and quality of life over time. The total participation includes assessments up to 6 months following the nerve stimulation treatment, allowing for observation of both short- and longer-term effects.

Researchers are evaluating whether the DeepMSI AI system can detect biomarkers of age-related macular degeneration AMD with sensitivity and specificity comparable to those of experienced clinicians. This observational study focuses on adults over 40 years old and aims to determine if AI analysis of retina images matches clinical interpretations. The study is sponsored by AI-Spectral and seeks to improve AMD detection using advanced imaging technology. Participants eyes will be imaged using the MSI-120 retina imaging device, and the images will be analyzed independently by the DeepMSI AI system and retina specialists. The study includes two groups eyes with AMD-related changes such as drusen or geographic atrophy, and healthy eyes from participants over 40 without any AMD or other retinopathies. AI results will not be shared with participants or treating clinicians during the study to avoid influencing care. Participants will have their retina images collected and analyzed, with researchers comparing AI and clinician findings to assess equivalency in detecting AMD biomarkers. The primary outcome is the comparison of sensitivity and specificity between DeepMSI AI and clinicians over an average follow-up of six months. The study involves no treatment administration, focusing solely on imaging and data collection during the participation period.

Researchers are evaluating the effectiveness of transcranial direct current stimulation tDCS combined with mindfulness delivered remotely through telemedicine in adults with unipolar depression. This randomized, double-blind, sham-controlled trial involves 25 adults diagnosed with major depressive disorder who are currently experiencing a major depressive episode. The study aims to understand how this combined treatment affects depression symptoms using established rating scales. Participants will be randomly assigned to one of two groups one receiving active tDCS along with mindfulness audio instruction and music, and the other receiving sham placebo electrical stimulation combined with guided mindfulness audio. The treatment is non-invasive and delivered remotely. The study includes multiple assessments over several weeks to monitor changes and effects. During the study, participants will complete various depression rating scales such as the Hamilton Depression Rating Scale HDRS, Quick Inventory of Depressive Symptomatology, and Montgomery-Asburg Depression Rating Scale at scheduled intervals. Researchers will assess symptom severity, quality of life, global clinical impression, and disability. The trial includes blinding integrity checks and collects data up to 13 weeks to monitor response and remission rates. Participants will be monitored for safety throughout the study.